Long-term safety of lamivudine treatment in patients with chronic hepatitis B. - Wikidata - awgldk - TriplyDB

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q44729211

about

Continued lamivudine for adults with lamivudine-resistant chronic hepatitis B virus infection Antiviral treatments for lamivudine-resistant chronic hepatitis B adult patients Current trends in management of hepatitis B virus reactivation in the biologic therapy era KASL clinical practice guidelines: management of chronic hepatitis B Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation Genetic variation of hepatitis B virus and its significance for pathogenesis The Role of Oxidative Stress and Antioxidants in Liver Diseases Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation Antiviral therapy for chronic hepatitis B: Combination of nucleoside analogs and interferon Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Liver safety assessment in special populations (hepatitis B, C, and oncology trials)Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis Current and future antiviral drug therapies of hepatitis B chronic infection Antiviral drug resistance: mechanisms and clinical implications Association of preexisting drug-resistance mutations and treatment failure in hepatitis B patients A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner.Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues.High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.Antiviral therapy and resistance with hepatitis B virus infection.Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment.Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa Clinical significance of hepatitis B e antigen level measurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.A cutting-edge view on the current state of antiviral drug development.Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy.Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Individualized management of pregnant women with high hepatitis B virus DNA levels.Antiviral treatment of chronic hepatitis B virus (HBV) infections Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice Review of hepatitis B therapeutics.Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy.Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil.

P2860

Q24185958-08EDD549-EAE1-4504-89B3-C8D0D605084E Q24241469-5011AC55-18C9-46AC-97B6-01AA6B65C618 Q24634879-985CBCA9-5A21-420F-91A7-FA94254DC3C0 Q26752475-6F32FA58-E862-4F32-8628-4D6FF2BB7867 Q26772036-5E7F13CC-5A3B-48BA-B4E2-CEABEBC5DBC5 Q26772348-8C9DBD1E-0855-4FD0-AC87-A70C7767918C Q26779146-56D4B929-B621-4428-A4EE-F8835E13B7A6 Q26781962-AC2997D3-13BF-45B7-B844-F00CC2E9DB61 Q26784241-E3F614DC-C3BF-4134-AEC3-3ADB069356EE Q26830435-ABEC642C-F2C0-4AA0-8513-929C0BF657A8 Q27000080-455ECA48-7CA2-4272-A22F-C08A232F0141 Q27008502-47914D62-584F-4716-9D0D-8DDCE26DB821 Q27008984-F24FED67-9B6B-4B02-8537-8014A91D297D Q28074579-70012F7D-0426-41E0-AB0A-1C8190D55667 Q28084820-97F2350B-A2E6-4016-AFDD-BF38DFC3847A Q28282376-89E1EF38-008D-4DDD-86B4-00D23B0F2DA4 Q28535003-05FD6BDF-9630-49DC-85AE-52946FF877A3 Q28552295-6F9072D7-2900-460C-B2F2-0D5D9797870C Q28704122-330FCF8C-CC05-4568-BEB4-0A514B2FA839 Q30440211-310FC9AB-1B2C-41FA-AFFB-19EE9FDF2726 Q33242705-98481247-91EF-4EA2-882D-1DD702FDB48D Q33492413-7C086824-70D8-42A8-8C2D-E51F8804CAF5 Q33627472-593DDB7D-12C1-4BB0-A785-B53CE48095AB Q33718935-2353F7D2-2E9D-4E2E-A072-F5A9DB0521CE Q33787531-9BA5837D-FFAE-42E1-95CB-1A2133B864F4 Q33797424-981D0D5F-041B-4B15-B07D-4838F26FD3E6 Q33869365-F3F1E34E-EF8A-40DB-B532-32A348F96D46 Q33869423-161B89DB-0207-4FA0-A015-714D33687188 Q34017787-0EFDF94D-0C30-417E-B59B-838E63DF7BB1 Q34024728-6FE0FADF-2933-4F72-887C-01330CE3ADC1 Q34036018-DFCE9CDC-0744-403C-A5DE-BEED8E8E1431 Q34080966-73DC02A7-FC25-414E-B24E-CE5B815A663F Q34130388-33BD9342-9DFF-4A67-AD9F-FD8FC4EDAF11 Q34137291-B8EF5DA7-7092-4244-BD0B-2D5A423BB42E Q34168470-1636B214-C701-4AD5-835C-9AD233A408D8 Q34223779-625A19B5-17A5-47D6-A95F-9B37FD2BD9FB Q34256062-9F17D833-52C2-4097-8BDB-CE107F4F591C Q34296410-B41813E6-0A6B-44B2-8963-A71C4D8725E2 Q34303163-B252CD38-9477-4973-8BE9-4D46D6F5B2D0 Q34362568-FD59FEA0-81C2-4A55-A842-443A5D70BB04

P2860

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q44729211

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@en

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@nl

type

label

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@en

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@nl

prefLabel

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@en

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@nl

P1433

Q44729211-FF6485A5-C174-4939-9777-54586A72E10C

P1476

Q44729211-0AF0E9AA-E915-4452-9A21-28200E8804C0

P2093

Q44729211-0A80B979-F99A-48C8-A6C5-D508C1F96D04

Q44729211-2AB93F26-D87C-4C61-9B19-DAC438D870F1

Q44729211-32AA5FF8-F0FB-42FB-AC29-91A4CE439395

Q44729211-53F76CA1-B01F-4CDC-9425-D71CE4BEB05C

Q44729211-629ED8F7-C2F0-408D-A854-AF3CD9878493

Q44729211-633CA7ED-FECF-4FE9-BBC1-F730F288A3AF

Q44729211-70BF1585-DC7D-4777-8B84-57D61B9EAA3A

Q44729211-73C2B52E-8D0E-4951-A1A5-DABD949D6487

Q44729211-76DFD2B0-1B6F-4E6C-AE2E-8B72A0C7D9BF

Q44729211-8990BC35-A375-43E3-974D-D97BF7B41E5E

P304

Q44729211-367469E9-FB8F-4E9A-BBCF-938161C1DF2A

P31

Q44729211-8363F9F6-651A-4567-AEC5-2286654AC91D

P356

Q44729211-4DD48E1E-6E9A-4D46-A075-3254AF43AF83

P407

Q44729211-0BCCDC13-4B8F-4B83-BAE2-68EE96F3B32F

P433

Q44729211-69E5193F-BBEA-40AE-A18F-5C0527A8C2B8

P478

Q44729211-026D4142-17D0-404D-86F0-32E9D15948EC

P577

Q44729211-294D84B5-AD57-4EAB-B25C-FC59657E9454

P698

Q44729211-26BA5D6F-273A-4527-80E6-7D2E7CBC6D0B

P921

Q44729211-973CDBEE-7EC0-48BF-82D3-E2A1E44D92AD

P356

J.GASTRO.2003.09.033

P1433

Gastroenterology

P1476

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

@en

P2093

Anna S F Lok

http://www.w3.org/2001/XMLSchema#string

Ching-Lung Lai

http://www.w3.org/2001/XMLSchema#string

Dorothea A Griffiths

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Eugene R Schiff

http://www.w3.org/2001/XMLSchema#string

Guang-Bi Yao

http://www.w3.org/2001/XMLSchema#string

Jules L Dienstag

http://www.w3.org/2001/XMLSchema#string

Mary Castiglia

http://www.w3.org/2001/XMLSchema#string

Nancy Leung

http://www.w3.org/2001/XMLSchema#string

Nancy R Little

http://www.w3.org/2001/XMLSchema#string

P304

1714-1722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2003.09.033

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14724824

http://www.w3.org/2001/XMLSchema#string

P921